Last reviewed · How we verify
ExoLuminate Study for Early Detection of Pancreatic Cancer
ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC). Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis. The goal of the study is to compare the performance of ExoVerita™ assay in early detection of PDAC to current standard-of-care methods of surveillance.
Details
| Lead sponsor | Biological Dynamics |
|---|---|
| Status | RECRUITING |
| Enrolment | 1000 |
| Start date | Mon Dec 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sat Jan 01 2028 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Pancreas Cancer
- Exosomes
- Extracellular Vesicles
- Pancreatic Neoplasms
Countries
United States